Pernix Therapeutics (PTX) Posts Q1 Loss of 62c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pernix Therapeutics Inc. Reports First Quarter 2015 Financial Results
May 1, 2015 6:50 AM EDTMORRISTOWN, N.J.--(BUSINESS WIRE)-- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2015.
Highlights of and subsequent to the quarter:
Acquired the Zohydro ER franchise from Zogenix, Inc. for $80.9 million in upfront cash, approximately 1.7 million shares of Pernix common stock, and potential regulatory and commercial milestone payments; Raised $130 million of gross proceeds through a private offering of 4.25% Convertible Senior Notes due 2021, funding the cash portion of the Zohydro® ER franchise... More